Table 1.
Patient and tumor characteristics
| Clinicopathological factors | Number of patients (n = 51) | % | |
|---|---|---|---|
| Age | Range | 25–68 | — |
| Median | 47.8 | — | |
| Tumor localization | Upper outer | 19 | 37.3% |
| Upper inner | 9 | 17.6% | |
| Lower outer | 6 | 11.8% | |
| Lower inner | 5 | 9.8% | |
| Central | 12 | 23.5% | |
| Histological type | Invasive ductal carcinoma | 39 | 76.5% |
| Invasive lobular carcinoma | 9 | 17.6% | |
| Composite carcinoma | 3 | 5.9% | |
| Tumor classification | T1 | 9 | 17.6% |
| T2 | 23 | 45.1% | |
| T3 | 11 | 21.6% | |
| T4 | 8 | 15.7% | |
| Clinical nodal status | N1 | 28 | 54.9% |
| N2 | 16 | 31.4% | |
| N3 | 7 | 13.7% | |
| Clinical AJCC stage | IIA (T1N1M0) | 7 | 13.7% |
| IIB (T2N1M0) | 19 | 37.3% | |
| IIIA (T1-3N1-3) | 13 | 25.5% | |
| IIIB (T4N1-2) | 7 | 13.7% | |
| IIIC | 5 | 9.8% | |
| ER | (−) | 22 | 43.1% |
| (+) | 29 | 56.9% | |
| PR | (−) | 24 | 47.1% |
| (+) | 27 | 52.9% | |
| HER-2 | (−) | 21 | 41.2% |
| (+) | 17 | 33.3% | |
| (++) | 8 | 15.7% | |
| (+++) | 5 | 9.8% | |
AJCC, American Joint Committee on Cancer; ER, estrogen receptor; HER-2, human epidermal growth factor receptor 2; PR, progesterone receptor.